As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
15 Analysts have issued a AVROBIO Inc forecast:
15 Analysts have issued a AVROBIO Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -73 -73 |
29%
29%
|
|
| EBIT (Operating Income) EBIT | -74 -74 |
30%
30%
|
|
| Net Profit | -66 -66 |
13%
13%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Alise Reicin |
| Founded | 2015 |
| Website | tectonictx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


